title: Unchanged global fibrinolytic capacity during the course of hematopoietic stem cell transplantation.
abstract: Hemostatic changes due to vascular endothelial damage are seen during the course of hematopoietic stem cell transplantation (HSCT). The fibrinolytic response to ongoing hemostatic activation in HSCT remains to be elucidated. Global fibrinolytic capacity (GFC) is a novel method, which reflects the amount of generated D-dimer when fibrinolysis of a freeze-dried fibrin clot is stopped by introducing aprotinin. GFC is sensitive to all the factors involved in the process of fibrinolysis. The aim of this study was to serially assess GFC at certain critical time points (days -1, +7, +14, +21 prior to and following stem cell infusion) during the course of HSCT. The study group comprised 16 patients with hematological malignancies (11 women, five men; median age 32+/-9 years) in whom HSCT had been performed. Thirty healthy adults (21 women, nine men; median age 31+/-7 years) served as controls. In this study, global fibrinolytic response, as reflected by GFC, was unchanged despite ongoing hemostatic activation, as indicated by D-dimer, moreover GFC remained stable, despite the development of thrombocytopenia associated with HSCT prior to platelet engraftment. Our results indicate that a global fibrinolytic response was impaired as a compensatory response to endothelial activation and to other hemostatic changes seen in HSCT. Further studies in larger HSCT populations are warranted to better understand the implications of these findings.
authors.affiliation: Department of Hematology, Hacettepe University Medical School, Sihhiye, Ankara, Turkey. saksu@hacettepe.edu.tr
authors.forename: Salih
authors.initials: S
authors.lastname: Aksu
authors.forename: Yavuz
authors.initials: Y
authors.lastname: Beyazit
authors.forename: Ibrahim C
authors.initials: IC
authors.lastname: Haznedaroglu
authors.forename: Hakan
authors.initials: H
authors.lastname: Goker
authors.forename: Murat
authors.initials: M
authors.lastname: Kekilli
authors.forename: Jale
authors.initials: J
authors.lastname: Karakaya
authors.forename: Ebru
authors.initials: E
authors.lastname: Koca
authors.forename: Deniz
authors.initials: D
authors.lastname: Cetiner
authors.forename: Nilgün
authors.initials: N
authors.lastname: Sayinalp
authors.forename: Yahya
authors.initials: Y
authors.lastname: Buyukasik
authors.forename: Osman I
authors.initials: OI
authors.lastname: Ozcebe
authors.forename: Serafettin
authors.initials: S
authors.lastname: Kirazli
authors.forename: Semra V
authors.initials: SV
authors.lastname: Dundar
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000737:chemistry / Q000378:metabolism*; D005342:Fibrinolysis / Q000502:physiology*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006487:Hemostasis / Q000502:physiology*; D006801:Humans; D008297:Male; D013997:Time Factors
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D